Alkermes plc is a biopharmaceutical company that focuses on central nervous system diseases such as such as schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 by Michael Wall.

When did Alkermes go public?

So, in July of 1991, Alkermes launched its IPO, which Pops recalls being rather modest by today's standards at a $60 million pre-money valuation.

Who bought Alkermes?

(NASDAQ: ALKS) and Elan Corporation, plc (NYSE: ELN) today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies (EDT), the profitable, world-class drug formulation and manufacturing business unit of Elan, in a cash and stock transaction currently valued at ...